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Abstract
Considerations regarding clinical effectiveness and cost are essential in comparing
the overall value of two treatments. There has been growing interest in methodology
to integrate cost and effectiveness measures in order to inform policy and promote
adequate resource allocation. The net monetary benefit aggregates information on dif-
ferences in mean cost and clinical outcomes; the cost-effectiveness acceptability curve
was then developed to characterize the extent to which the strength of evidence regard-
ing net monetary benefit changes with fluctuations in the willingness-to-pay threshold.
Methods to derive insights from characteristics of the cost/clinical outcomes besides
mean differences remain undeveloped but may also be informative. We propose a
novel probabilistic measure of cost-effectiveness based on the stochastic ordering of
the individual net benefit distribution under each treatment. Our approach is able
to accommodate features frequently encountered in observational data including con-
founding and censoring, and complements the net monetary benefit in the insights it
provides. We conduct a range of simulations to evaluate finite-sample performance and
illustrate our proposed approach using simulated data based on a study of endometrial
cancer patients.
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1 Introduction
Policy decisions are often informed by aggregate information on cost and clinical effectiveness.
Several measures have been previously proposed to compare the cost-effectiveness of two
interventions. Arguably, the simplest of these measures is the incremental cost-effectiveness
ratio (ICER), given by the difference in mean cost divided by the difference in mean clinical
measure [1, 2, 3]. When the ICER lies below a pre-determined willingness-to-pay (WTP)
threshold, the experimental treatment is deemed cost-effective. The net monetary benefit
(NMB) is an equivalent measure to the ICER that was proposed to avoid a singularity in
the denominator, as well as known challenges associated with interval estimation of ratio
parameters [4, 5]. The NMB has been used to compare cost-effectiveness in many recent
studies [6, 7, 8, 9, 10].
The cost-effectiveness acceptability (CEA) curve was proposed as a probabilistic repre-
sentation of strength of evidence regarding NMB; its function is to elucidate how conclusions
vary with changes in the WTP [11]. The CEA is defined as the proportion of positive boot-
strapped estimates of the NMB; it is sometimes loosely referred to as the ”probability of
cost-effectiveness,” [12, 13, 14] but more closely resembles a frequentist p-value [15]. The
CEA has been used as a primary tool to advocate policy changes. Delaney et al., for in-
stance, utilize a CEA as evidence in support of initial endoscopy in dyspepsia patients [16],
and mental health studies have commonly included CEAs for decision-making purposes in
various interventions, sometimes under the name ”probabilistic sensitivity analysis” [17, 18].
However, Barton et al. note that the CEA, despite its widespread use, does not alone pro-
vide a path for optimal decision-making as it does not provide insights into the extent of
cost-effectiveness [19].
Some have proposed alternative graphical tools to the CEA in response to the challenges
associated with interpreting it as a probability of cost-effectiveness within the frequentist
paradigm. One approach, proposed by Heitjan et al., was to re-frame the NMB and ac-
ceptability curve within a Bayesian paradigm so that a probabilistic interpretation would
be warranted [20, 21]. Hoch and Blume present a likelihood ratio approach based on a
pre-specified alternative hypothesis [15]. These approaches, like the CEA, are still guided
by inference and strength of evidence regarding the NMB, quantifying either the degree of
belief regarding the mean cost-effectiveness a posteriori (Bayesian methods), or the strength
of evidence in support of a positive NMB (likelihood methods).
While the CEA provides insights into sensitivity of conclusions regarding mean clin-
ical/cost outcome combinations to fluctuations in the WTP, a probabilistic measure of
cost-effectiveness magnitude—i.e., a parameter that quantifies the frequency with which
treatment produces more desirable clinical/cost outcome combinations—can summarize the
distribution of the cost/clinical outcomes as a whole in a way that complements insights
from mean differences. In this paper, we define the net benefit separation (NBS) as the
probability that an observation from a hypothetical population in which all patients receive
treatment has greater individual net benefit than an observation from a hypothetical pop-
ulation in which all patients receive the control. This gives rise to a visualization tool in
which the NBS is plotted over a range of willingness-to-pay thresholds, which we term the
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cost-effectiveness determination (CED) curve. In this paper, we will further demonstrate
how weighting and standardization can be used to estimate the NBS and its corresponding
CED curve when outcomes are right-censored and the data are subject to confounding.
The remainder of this paper is organized as follows. In Section 2, we provide a review of
the net monetary benefit and its associated cost-effectiveness acceptability curve. In Section
3, we define the net benefit separation and its associated determination curve. In Section 4,
we propose an estimation procedure to estimate net benefit separation using observational
data. In Section 5, we present results from a simulation study in order to understand the
finite-sample properties of our methods. In Section 6, we present an illustration of these
methods using simulation-based data from a prior study of endometrial cancer patients [22].
We conclude with a discussion of our findings in Section 7.
2 Review of the Net Monetary Benefit and Acceptability Curve
2.1 The net monetary benefit
Let i = 1, . . . , N index independently sampled study participants, and let Ai denote bi-
nary treatment. Let Si denote the clinical measure (i.e., the outcome that determines the
treatment’s effectiveness), and Yi the cost. For example, S could be systolic blood pressure
reduction or survival time, and Y could be initial treatment cost or total medical cost billed
through some time range. The net monetary benefit (NMB) is defined as follows:
NMB(λ) = λ(E[S|A = 1]− E[S|A = 0])− (E[Y |A = 1]− E[Y |A = 0]).
Here, λ denotes the WTP and is defined as the maximum cost one would be willing to pay
for a one-unit improvement in S associated with treatment A = 1 (for example, $50,000 for
year of life saved). Note that NMB(λ) > 0 indicates treatment A = 1 is more cost-effective
on average, while NMB(λ) < 0 indicates the reverse.
2.2 The cost-effectiveness acceptability curve
The CEA is defined according to the following procedure:
1. Define some range Λ of possible willingness-to-pay thresholds.
2. For k = 1, . . . , K:
• Draw a full-sized bootstrap replicate from the set {Ai, Si, Yi}Ni=1.
• Compute N̂MBk(λ) using the bootstrapped data for each λ ∈ Λ.
3. For λ ∈ Λ, the acceptability curve is defined as:
CEA(λ) = K−1
K∑
k=1
1(N̂MBk(λ) > 0).
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While sometimes stated as the probability of cost-effectiveness [12, 13, 23, 14, 11], this is more
accurately described as one minus a one-sided bootstrapped p-value of the lesser alternative
that the control is more cost-effective on average. The limiting behavior of the CEA can
be described as follows. First fix N = n: at λ = 0, clinical effects are not considered, and
as λ increases, the mean cost difference wanes in its influence on CEA(λ). Now consider
asymptotics in N , and suppose first that the difference in mean clinical outcome is nonzero
(the non-degenerate case). As N grows, the CEA converges point-wise to a step function:
lim
N,K−→∞
CEA(λ) =

1 for λ > E[Y |A=1]−E[Y |A=0]E[S|A=1]−E[S|A=0]
0.5 for λ = E[Y |A=1]−E[Y |A=0]E[S|A=1]−E[S|A=0]
0 for λ < E[Y |A=1]−E[Y |A=0]E[S|A=1]−E[S|A=0]
.
If instead the difference in mean clinical outcome is zero, then
lim
N,K−→∞
CEA(λ) =

1 ∀λ if E[Y |A = 1] < E[Y |A = 0]
0.5 ∀λ if E[Y |A = 1] = E[Y |A = 0]
0 ∀λ if E[Y |A = 1] > E[Y |A = 0]
.
In the non-degenerate case, the limit of the CEA informs the value of λ at which the treat-
ments are equally cost-effective on average (i.e., at the ICER); equivalently, it informs the
values of λ at which the NMB is positive, regardless of magnitude. Figure 1 illustrates the
CEA’s limiting behavior when treatment produces higher mean cost and clinical benefit.
Figure 1: Illustration of the limiting behavior of the cost-effectiveness acceptability curve.
Here, the experimental treatment is more costly on average, but also yields greater mean
clinical benefit (a prototypical setting in which a cost-effectiveness analysis would be war-
ranted). Note that the step from zero to one in the limit of the CEA occurs precisely at the
value of the ICER.
For a given λ, a higher CEA value indicates stronger support in favor of cost-effectiveness
for treatment A = 1; however, values closer to zero do not distinguish between ”absence of ev-
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idence for the experimental treatment’s cost-effectiveness” and ”evidence of cost-effectiveness
for the control treatment.” This challenge regarding lack of symmetry can be avoided by in-
stead plotting the estimated NMB and confidence intervals across a range of λ. This graph-
ical representation accomplishes the goal of the CEA (which is to provide insights into the
sensitivity of conclusions regarding the value of the NMB to changes in λ) with the added
advantage of depicting both the point and interval estimates.
3 Net Benefit Separation: A Probabilistic Approach
Recall that (S, Y ) denotes the clinical/cost outcome pair. Define B(λ) = λS − Y to be the
individual net benefit (INB). Following the potential outcomes notation [24], let (Sa, Y a)
denote the clinical and cost outcome pair under treatment A = a, and Ba the INB under
treatment A = a. One straightforward probabilistic metric of cost-effectiveness is defined
at the subject specific level: θ∗(λ) = P(B1i (λ) > B
0
i (λ)). This can be described as the
probability that the treatment is cost-effective for a random subject. Because only one
potential outcome pair can be observed per subject, θ∗(λ) is not identifiable without imposing
unrealistic and untestable assumptions (e.g., uncorrelatedness of B0i (λ) and B
1
i (λ)).
We instead propose a measure of stochastic ordering of the marginal distributions under
each hypothetical comparator treatment. To avoid notational confusion, let Ba(λ) denote
a randomly sampled value for B(λ) under the setting in which everyone receives treatment
A = a. We define the net benefit separation (NBS) by θ(λ) = P(B1(λ) > B0(λ)). In essence,
the NBS targets the area under the receiver operating characteristic curve, frequently used
in the evaluation of diagnostic measures, and is so named as it takes on the value one only
when the distribution of INBs under A = 1 stochastically dominates the distribution under
A = 0, and zero if the reverse is true. The NBS takes on the value of one-half, for instance,
when the treatment has null clinical and cost effects (Figure 2).
3.1 The case for considering both the NMB and NBS
The NMB and NBS can be seen as complementary measures of cost-effectiveness (the former
is a comparison of population means, while the latter is a measure of stochastic ordering).
It is possible for the two to provide seemingly contradictory stories at times. In particular,
NMB(λ) > 0 6⇔ θ(λ) > 0.5. Particularly since it is not clear that one of these measures is
uniformly more informative than the other, this provides a case for considering both NMB
and NBS in a cost-effectiveness analysis.
Imagine a scenario in which θ(λ) ≈ 0.5, but NMB(λ) > 0. This can happen, for instance,
when there is a high level of right-skewness that drives a mean difference. In such a setting,
one may put more weight on θ(λ) in regards to decisions on whether to apply the experimental
treatment to the entire population. On the other hand, imagine a scenario in which θ(λ)
is very high, but that NMB(λ) ≈ 0. This can happen, for instance, when a large segment
of the population exhibits a modest level of treatment benefit with very high precision (i.e.,
low variability).
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Figure 2: Illustration of NBS under four scenarios. In the first (upper left), treatment
A = 1 dominates A = 0; the reverse is true in the second scenario (upper right). In the
third scenario (lower left), the treatments are comparably cost-effective, and the the fourth
scenario (lower right), treatment A = 1 is moderately more cost-effective as compared to
A = 0.
These examples, while hypothetical, underscore the tension between scientific questions
pertaining to whether a treatment tends to produce more desirable outcomes on average
and scientific questions pertaining to whether a treatment tends to produce more desirable
outcomes in probability. Evidence of discordance between NMB(λ) and θ(λ) can spark
further exploration in order to learn about possible sources for heterogeneity.
3.2 The determination curve and its limiting behavior
The limiting behavior of θ(λ) can be characterized as follows. We have that θ(λ = 0) =
P(Y0 > Y1) and limλ−→∞ θ(λ) = P(S1 > S0), where (Sa, Ya) denotes a randomly sampled
clinical and cost outcome pair under treatment A = a. We define the cost-effectiveness
determination (CED) curve as {(λ, θ(λ)) : λ ∈ Λ}, where again Λ denotes a reasonable set
of WTP threshold values.
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4 Estimation
4.1 Randomized trials with no censoring
To orient our discussion of estimation, we first consider the idealized setting of a randomized
trial in which there is no censoring (this can equivalently be thought of as a randomized
trial that considers a non-survival clinical measure). A nonparametric estimate of θ(λ) can
be constructed in this case: letting k = 1, . . . ,
∑N
i=1(1− Ai) ≡ N0 index the patients in the
control arm and l = 1, . . . , N1 ≡ N −N0 index the patients in the experimental arm,
θ̂(λ) =
1
N0N1
N0∑
k=1
N1∑
l=1
1 (B1l(λ) > B0k(λ))
is trivially unbiased and consistent for θ(λ). It is perhaps better expressed using the equiv-
alent and less computationally taxing scaled variant of the Wilcoxon Rank-Sum statistic:
θ̂(λ) =
1
2N0
(
1
N1
N∑
i=1
2AiRi(λ)−N1 − 1
)
,
where Ri(λ) denotes the rank of the the pooled INBs. In this setting, the sets {B0k(λ)}Ak=0
and {B1l(λ)}Al=1 each form nonparametric estimates of the marginal distributions for B0(λ)
and B1(λ), respectively. The remainder of this section is therefore geared toward approaches
for estimating those marginal distributions under more complex (but more realistic) settings
in which there is confounding and survival time is the clinical outcome.
4.2 Semiparametric standardization
Suppose we are in the setting of observational data. Letting L denote (observed) confounders,
the NBS can be expressed as:
θ(λ) =
∫
θ(λ|L = `)dF`(L).
We may then employ Monte-Carlo standardization for estimation:
1. Define some range Λ of possible willingness-to-pay thresholds.
2. Estimate the distribution of L (e.g., via the empirical F̂N(L)).
3. Fit models for f(S|L, A) and f(Y |L, A, S).
4. For each a = 0, 1:
• Generate K random draws L˜k from F̂N(L).
• Generate K random draws: S˜k from f̂(S|L˜, A = a) and Y˜k from f̂(Y |L˜, A =
a, S˜k), as estimated in Step 3.
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5. Compute the ranks R˜k(λ), using the pooled data, of the K INBs from the realizations
drawn from a = 1.
6. For each λ ∈ Λ, an estimate the net benefit separation is given by:
θ̂(λ) =
1
2K
(
1
K
K∑
k=1
2R˜i(λ)−K − 1
)
.
This method specifies parametric models for the conditional distributions of S and Y , but
not for the distribution of the confounders. Importantly, the parametric models can be quite
flexible, easily accommodating regression splines and zero-inflation of cost using a two-part
model [25].
4.3 Addressing censoring and truncated cost
Suppose now that S is survival time. We further assume that Y is considered over time
range [0, τ ]. Let C denote the censoring time; in practice, X = min(S,C) is observed. Let
δ = 1(C < S) denote the indicator of censored survival time, and δ∗ = 1(C < min(S, τ))
the indicator of censored costs. Inverse probability-of-censoring weights (IPCW) must be
included to estimate f(Y |L, A) owing to informative censoring induced by heterogeneity in
cost-accrual rates [26, 27, 28]. Weights can be obtained via the Kaplan-Meier method. Let
G(t) = P(C ≥ t), and Ĝ(t) the Kaplan-Meier (KM) estimator based on (Xi, δ∗i ). If covariates
are discrete, stratification is possible; for other cases (e.g., continuous covariates), we may
instead use employ the stratified Cox proportional hazards model [29]:
h(t|V ,W ) = exp(φTW (t))hV (t),
where V denotes stratification variables and W other covariates. Here, h(·) denotes the
hazard function for censoring, and we assume that (S, Y ) ⊥ C|V ,W ; covariates in V and
W may include those in L. Letting S∗ = min(S, τ), the probability of being observed can
be estimated by:
Ĝi(S
∗
i ) = exp
(
−
N∑
j=1
δj1(V i = V j, S
∗
i > Xj) exp(φ̂
T
W i(Xj))∑N
k=1 1(V i = V k, Xk ≥ Xj) exp(φ̂
T
W k(Xj))
)
.
Note that φ̂ denotes the partial likelihood estimator [30].
4.4 Interval estimation and inference
Confidence intervals can be formed using the nonparametric bootstrap [31]. In the case of
Section 4.1.,
√
N1(θ̂(λ)−1/2) −→d N (0, (r+1)/(12r)) under the null hypothesis H0 : θ(λ) =
1/2 and equal variances, where r denotes the randomization ratio limN→∞N0/N1. This may
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be used for asymptotic inference. Otherwise, hypothesis testing can also be conducted using
the nonparametric bootstrap.
5 Simulation Study
We conduct a simulation study to evaluate the performance of θ̂(λ) under two sample sizes
(N = 500 and N = 5,000) and two censoring rates (10% and 25%). Covariates are sim-
ulated as L1 ∼ N (µ = 0, σ = 1) and L2 ∼ Bernoulli(0.5), and treatment is given by
A ∼ Bernoulli(p = expit(L1)). Survival is generated as S ∼ Weibull(shape = 2, scale =
exp(α0+0.2L1+0.2L2+αAA)), and censoring is generated as C ∼Weibull(shape = 2, scale =
exp(β0 + 0.1L2)). We generate the cost such that log(Y ) ∼ N (µ = 4.2 + 0.002S + γAA, σ =
0.4). The parameter β0 controls the censoring rate and is set to β0 = 5.65 for 10% censoring
(low) and β0 = 5.1 for 25% censoring (high). We consider two simulation scenarios. The
first is a null scenario in which the treatment has no impact on cost or survival (α0 = 4.5
and αA = γA = 0); the second is such that treatment is associated with an increase in both
cost and survival (α0 = 4.05, αA = 0.7, and γA = 0.1). We consider λ = 2 and λ = 12 as
examples.
For each case, we conduct one-thousand replicates with K = 300 bootstrap replicates and
M = 5,000 Monte-Carlo iterations. The distribution of (L1, L2) was estimated nonparamet-
rically using the empirical distribution for the standardization procedure. The Kaplan-Meier
estimator is used to determine the IPCW weights, stratified by L2. We report the mean esti-
mate θ̂(λ) across simulations, as well as the average estimated standard error and empirical
standard error across Monte-Carlo replicates.
Tables 1 and 2 present results for each scenario. The proposed procedure is able to
estimate θ(λ) with low bias, and the nonparametric bootstrap standard error adequately
represents the true repeat-sample variability. For lower samples sizes, the bootstrap standard
error slightly underestimates the true standard error on average for lower values of λ, and
slightly overestimate the standard error for higher values of λ. This bias dissipates with a
larger sample size.
Table 1: Performance of θ̂(λ) under Scenario 1 (no treatment effect). Included are the mean
estimate, empirical standard error (ESE), and mean estimated standard error.
Censoring N λ θ(λ) Est. ESE ŜE
10% 500 2 0.500 0.502 0.0265 0.0230
10% 500 12 0.500 0.501 0.0260 0.0245
10% 5,000 2 0.500 0.500 0.0120 0.0114
10% 5,000 12 0.500 0.500 0.0119 0.0117
25% 500 2 0.500 0.500 0.0261 0.0240
25% 500 12 0.500 0.500 0.0252 0.0257
25% 5,000 2 0.500 0.500 0.0122 0.0117
25% 5,000 12 0.500 0.500 0.0117 0.0120
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Table 2: Performance of θ̂(λ) under Scenario 2 (treatment increases cost and survival time).
Included are the mean estimate, empirical standard error (ESE), and mean estimated stan-
dard error.
Censoring N λ θ(λ) Est. ESE ŜE
10% 500 2 0.743 0.731 0.0242 0.0198
10% 500 12 0.780 0.771 0.0198 0.0207
10% 5,000 2 0.743 0.730 0.0097 0.0096
10% 5,000 12 0.780 0.771 0.0093 0.0096
25% 500 2 0.743 0.731 0.0242 0.0216
25% 500 12 0.780 0.771 0.0203 0.0213
25% 5,000 2 0.743 0.730 0.0110 0.0105
25% 5,000 12 0.780 0.771 0.0099 0.0099
6 Application
We conduct a cost-effectiveness analysis using a simulation-based data set motivated from
a prior study of survival and total medical costs in post-hysterectomy stage-I and stage-II
endometrial cancer patients [22]. We fit a sequence of flexible models on the variables from
the original database and simulated a data set of equal size from the estimated models. Our
reasons for taking this approach are twofold: (1) doing so allows us to make the data set
fully available; we would not be able to do so otherwise due to the proprietary nature of the
data, and (2) the proportion of individuals having an event by the study’s end was low due
to insufficient follow-up time. Hence, outcomes were simulated over a ten-year window using
an aggregate of the original data and estimates from the literature [32, 33]. We provide the
simulated data set and code in the supplementary materials. Results are intended solely for
illustration purposes.
Post-surgery, endometrial cancer patients may receive adjuvant treatment with radiation
therapy (RT), chemotherapy (CT), or neither [34]. Though there are apparent survival
advantages associated with adjuvant RT and CT, little has been done to elucidate the cost-
effectiveness of either. Our illustration focuses on determining cost-effectiveness associated
with each of adjuvant RT alone and adjuvant CT alone received two to four months post-
surgery relative to control.
6.1 Description of data and analysis
Covariates include age of diagnosis, Charlson co-morbidity index [35], number of prior hos-
pitalizations, cancer stage, and prior receipt of RT or CT. These data include N = 13,526
patients. The mean age of diagnosis was 73.7 years (SD = 6.59 years), and 93.6% were
diagnosed with stage I cancer. At baseline, 5.99% of patients had received RT and 0.55%
had received CT. Through the two-to-four month window, 25.4% received RT and 2.25%
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received CT (0.79% received both RT and CT). A total of 7,720 deaths occurred (57.0%)
and 8,762 patients (64.7%) had complete cost data.
We employ the procedure outlined in Section 4.2 and incorporate weights from the Cox
model as outlined in Section 4.3. We utilize the empirical joint distribution of the baseline
covariates, and incorporate each covariate as a predictor of censoring time. We fit a para-
metric Weibull model to the survival distribution conditional on covariates and treatment
(each of RT and CT). We estimate the distribution of costs using a two-part zero-inflation
model (a logistic model for the probability of zero-costs, followed by a log-normal model
for nonzero costs). Quantiles from K = 1,000 bootstrap replicates were used to formulate
95% confidence intervals, and M = 10,000 replicates were used for the Monte-Carlo draws
associated with our standardization procedure.
Our target parameters include θR(λ) and θC(λ), which are defined by comparing: (1)
RT without CT to control, and (2) CT without RT to control, respectively (where control is
defined as no RT or CT). We additionally target NMBR(λ) and NMBC(λ), which correspond
to the net monetary benefit based on comparisons (1) and (2). We primarily consider a range
of 50 to 120 for λ (in units of thousands of USD over one year), though we extend the range
in order to illustrate limiting behavior. In our analysis, the NMB is determined using the
Monte-Carlo draws from the standardization procedure.
6.2 Results
Table 3 presents the results of our analysis for the boundary values of λ under primary con-
sideration. As an example of how to interpret the estimated NBS, θ̂C(λ), consider a WTP
threshold of $120,000, and imagine two hypothetical situations: one in which the population
receives CT (but no RT), and another in which the population does not receive adjuvant
RT or CT. We estimate that the INB from the individual sampled from the RT population
would be higher 67% of the time upon repeated random sampling from these two hypothet-
ical scenarios, with a 95% CI of (63%, 72%). Figure 3 presents the CED curves for each
comparison. Note that θ̂R(0) and θ̂C(0) are both smaller than 0.5, corresponding to higher
costs in the treatment groups. At the lowest value of the WTP used for primary considera-
tion ($50,000), these results suggest cost-effectiveness for both RT and CT as compared to
control.
Table 3: Point estimates and 95% confidence intervals for parameters of interest (columns)
for the lower and upper values of interest for the WTP (rows). Confidence intervals are
based on the 2.5th and 97.5th quantiles of the nonparametric bootstrap. Note that λ and
NMB are in units of thousands of dollars.
λ θR θC NMBR NMBC
50 0.59 (0.58, 0.61) 0.63 (0.60, 0.69) 46 (38, 69) 70 (26, 126)
120 0.60 (0.59, 0.63) 0.67 (0.63, 0.72) 141 (127, 182) 261 (185, 381)
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Table 3 additionally presents the estimated NMB at the same values of λ along with 95%
confidence intervals. Figure 4 depicts the estimated NMB, with confidence intervals included
for the primary range of λ. Similarly to the NBS, the confidence intervals do not include
zero, suggesting evidence of cost-effectiveness as measured by mean differences. Figure 5
depicts corresponding CEA curves, which suggest strong evidence that both RT and CT are
cost-effective relative to control on average for λ > 50. Moreover, the strength of evidence is
not sensitive to changes in λ over the range of interest (note this would not be so for lower
values of λ). These insights could also be gleaned from examination of Figure 4.
In this example, we find that the results from the NBS are consistent with those of the
NMB, suggesting that both RT and CT are cost-effective relative to control.
Figure 3: Cost-effectiveness determination curve for RT (left) and CT (right) vs. control over
the willingness-to-pay range of interest (bold). Corresponding point-wise confidence intervals
are included. For the purposes of illustrating the scope of curve behavior, we extend the
range of λ beyond the range of interest (shown in lighter gray).
Figure 4: Plot of the NMB for RT (left) and CT (right) vs. control over the willingness-to-
pay range of interest (bold). For the purposes of illustrating the scope of curve behavior, we
extend the range of λ beyond the range of interest (shown in lighter gray).
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Figure 5: Cost-effectiveness acceptability curve for RT (left) and CT (right) vs. control over
the willingness-to-pay range of interest (bold). For the purposes of illustrating the scope
of curve behavior, we extend the range of λ beyond the range of interest (shown in lighter
gray).
7 Discussion
In this paper, we have first summarized the net monetary benefit and its corresponding
acceptability curve, both of which are standard in cost-effectiveness analysis. We stated
the proper interpretation of results from these approaches and underscored some of the
limitations associated with current methodology.
Our proposed novel metric, the NBS, is a probabilistic population parameter that quan-
tifies the magnitude of cost-effectiveness, having an interpretation similar in spirit to that of
the area under a receiver operating characteristic curve in diagnostic testing. Our approach
to estimation can accommodate challenges typically encountered in observational studies
such as confounding and censoring via standardization and inverse probability weighting,
respectively.
The limitations of the acceptability curve that we have delineated do not generally apply
to the net monetary benefit as a whole. The net monetary benefit is a summary of average
cost-effectiveness and is useful in its own right. In order to graphically understand how the
magnitude of the net monetary benefit and evidence of a non-zero average effect on cost-
effectiveness change across the willingness-to-pay, we demonstrate that one may plot the
estimated net monetary benefits and respective confidence intervals across values of λ with
no need to consider the acceptability curve.
In Section 3.1, we describe scenarios in which the NMB and NBS could provide seemingly
contradicting information. This potential dichotomy cannot be resolved without fully under-
standing the context of the treatment and disease setting, including each treatment’s safety
profile and the clinical outcomes under consideration. It also certainly cannot be resolved
unless both measures are computed and understood. A discordance between the two metrics
would likely prompt subgroup analyses based on important variables to try to reconcile the
systematic sources of heterogeneity; we are currently developing approaches for subgroup
analysis in cost-effectiveness.
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One potential advantage of the net monetary benefit is the well-ordering/transitivity
property associated with simultaneous comparison of multiple competing treatment regimes.
That is, if treatment A is better than treatment B and treatment B is better than treatment
C, then treatment A will be better than treatment C when ”better” means a higher NMB. It
is known that transitivity does not always hold with measures of stochastic ordering like the
NBS. However, the NBS satisfies the previously unaddressed methodological gap pertaining
to the lack of a sensible probabilistic measure of cost-effectiveness magnitude.
Issues surrounding unobserved confounding apply to both the NMB and the NBS ap-
proach, and always merits close scrutiny in observational data. The risk of bias due to
unobserved confounding is always real in observational data, although care can be taken in
many cases at the data collection stage in order to to mitigate the impact. Approaches to
assess sensitivity of results to the assumption of no unmeasured confounding would be of
interest in this setting [36].
Our application is designed to illustrate a properly conducted cost-effectiveness analysis—
one in which insights regarding both the net monetary benefit and net benefit separation are
aggregated to paint a complete picture regarding treatment’s cost-effectiveness. Importantly,
our method for determining the NMB in this example is distinct from that employed in prior
literature. Li et al. [23] propose IPCW and propensity-score weights in order to estimate
the NMB; this approach is based on restricted mean survival time, in which the restriction
is to the upper bound on censoring time. Since our parametric approach for estimating the
survival distribution does not demand restriction, considering the semi-parametric approach
of Li et al. would induce an incongruity in a comparison of the two cost-effectiveness methods.
14
References
[1] Polsky D, Glick H, Willke R et al. Confidence intervals for cost-effectiveness ratios: a com-
parison of four methods. Health Economics 1997; 6(3): 243–252.
[2] Willan A and Briggs A. Statistical Analysis of Cost-Effectiveness Data, volume 37. John Wiley
& Sons, 2006.
[3] Willan A and O’Brien B. Confidence intervals for cost-effectiveness ratios: an application of
Fieller’s theorem. Health Economics 1996; 5(4): 297–305.
[4] Briggs A, Wonderling D and Mooney C. Pulling cost-effectiveness analysis up by its bootstraps:
A non-parametric approach to confidence interval estimation. Health Economics 1997; 6(4):
327–340.
[5] Heitjan D, Moskowitz A and Whang W. Problems with interval estimates of the incremental
cost-effectiveness ratio. Medical Decision Making 1999; 19: 9–15.
[6] Leppert M, Poisson S, Carroll J et al. Cost-effectiveness of patent foramen ovale closure versus
medical therapy for secondary stroke prevention. Stroke 2018; 49: 1443–1450.
[7] Liao C, Tan E, Chen C et al. Real-world cost-effectiveness of laparoscopy versus open colectomy
for colon cancer: a nationwide population-based study. Surgical Endoscopy 2017; 31: 1796–
1805.
[8] Zhang T, Xiang J, Cui B et al. Cost-effectiveness analysis of fecal microbiota transplantation
for inflammatory bowel disease. Oncotarget 2017; 8: 88894–88903.
[9] Maru S, Byrnes J, Carrington M et al. Cost-effectiveness of home versus clinic-based man-
agement of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized
trial cohort - the WHICH? study (which heart failure intervention is most cost-effective &
consumer friendly in reducing hospital care). International Journal of Cardiology 2015; 201:
368–375.
[10] Shafrin J, Skornicki M, Brauer M et al. An exploratory case study of the impact of expanding
cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell
lung cancer in canada: Does it make a difference? Health Policy 2018; 122: 607–613.
[11] M L and N Z. Definition, interpretation and calculation of cost-effectiveness acceptability
curves. Health Economics 2000; 9.
[12] Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of pa-
rameter uncertainty. Value in Health 2005; 8: 1–2.
[13] Fenwick E, O’Brien B and Briggs A. Cost-effectiveness acceptability curves–facts, fallacies and
frequently asked questions. Health Economics 2004; 13: 405–415.
[14] Fenwick E, Marshall D, Levy A et al. Using and interpreting cost-effectiveness acceptability
curves: an example using data from a trial of management strategies for atrial fibrillation.
BMC Health Services Research 2006; 6.
[15] Hoch J and Blume J. Problems with interval estimates of the incremental costeffectiveness
ratio. Journal of Health Economics 2008; 27: 476–495.
15
[16] Delaney B, Wilson S, Roalfe A et al. Cost effectiveness of initial endoscopy for dyspepsia in
patients over age 50 years: a randomised controlled trial in primary care. The Lancet 2000;
356(9246): 1965–1969.
[17] Ahern S, Burke L, McElroy B et al. A cost-effectiveness analysis of school-based suicide
prevention programmes. European Child & Adolescent Psychiatry 2018; 27: 1295–1304.
[18] Hunter R, Nazareth I, Morris S et al. Modelling the cost-effectiveness of preventing major
depression in general practice patients. Psychological Medicine 2014; 44: 1381–1390.
[19] Baron G, Briggs A and EA F. Optimal cost-effectiveness decisions: the role of the cost-
effectiveness acceptability curve (ceac), the cost-effectiveness acceptability frontier (ceaf), and
the expected value of perfection information (evpi). Value Health 2008; 13: 886–897.
[20] Heitjan D, Moskowitz A and Whang W. Bayesian estimation of cost-effectiveness ratios from
clinical trials. Health Economics 1999; 8(3): 191–201.
[21] Heitjan D, Kim C and Li H. Bayesian estimation of cost-effectiveness from censored data.
Statistics in Medicine 2004; 23: 886–897.
[22] Spieker A, Ko E, Roy J et al. Nested g-computation: A causal approach to analysis of
censored medical costs in the presence of time-varying treatment. Under review; arXiv preprint
arXiv:170508742 2019; .
[23] Li J, Vachani A, Epstein A et al. A doubly robust approach for costeffectiveness estimation
from observational data. Statistical Methods in Medical Research 2018; 27(10): 3126–3138.
[24] Rubin D. Bayesian inference for causal effects: The role of randomization. The Annals of
Statistics 1978; 6(1): 34–58. DOI:101214/aos/1176344064.
[25] Leung S and Yu S. On the choice between sample selection and two-part models. Journal of
Econometrics 1996; 72(1): 197–229.
[26] Spieker A, Roy J and Mitra N. Analyzing medical costs with time-dependent treatment: The
nested g-formula. Health Economics 2018; 27(7): 1063–1073.
[27] Lin D. Linear regression analysis of censored medical costs. Biostatistics 2000; 1(1): 35–47.
[28] Li J, Handorf E, Bekelman J et al. Propensity score and doubly robust methods for estimating
the effect of treatment on censored cost. Statistics in Medicine 2016; 35(12): 1985–1999.
[29] Cox D. Regression models and life-tables. Journal of the Royal Statistical Society, Series B
1972; 34: 187–220.
[30] Cox D. Partial likelihood. Biometrika 1975; 62: 269–276.
[31] Davison A and Hinkley D. Bootstrap Methods and Their Application. New York, NY: Cam-
bridge University Press, 1997.
[32] Shaeffer D and Randall M. Adjuvant radiotherapy in endometrial carcinoma. The Oncologist
2008; 10: 623–631.
16
[33] Susumu N, Sagae S, Udagawa Y et al. Randomized phase III trial of pelvic radiotherapy
versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk
endometrial cancer: a japanese gynecologic oncology group study. Gynecologic Oncology 2008;
108: 226–233.
[34] Braun M, Overbeek-Wager E and Grumbo R. Diagnosis and management of endometrial
cancer. American Family Physician 2016; 93.
[35] Charlson M, TP S, Peterson J et al. Validation of a combined comorbidity index. Journal of
Clinical Epidemiology 2016; 47: 1245–1251.
[36] Handorf E, Bekelman J, Heitjan D et al. Evaluating costs with unmeasured confounding:
A sensitivity analysis for the treatment effect. The Annals of Applied Statistics 2013; 7(4):
2062–2080.
17
